Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

R. Brown, Jennifer; Eichhorst, Barbara; Hillmen, Peter; Jurczak, Wojciech; Kaźmierczak, Maciej; Lamanna, Nicole; O’Brien, Susan; S. Tam, Constantine; Qiu, Lugui; Zhou, Keshu; Šimkovič, Martin; Mayer, Jiřı́; Gillespie-Twardy, Amanda; Ferrajoli, Alessandra; Ganly, Peter; Weinkove, Robert; Grosicki, Sebastian; Mital, Andrzej; Robak, Tadeusz; Österborg, Anders; Yimer, Habte; Salmi, Tommi; Wang, Megan-Der-Yu; Fu, Lina; Li, Jessica; Wu, Kenneth; Cohen, Aileen; Shadman, Mazyar

doi:10.1056/nejmoa2211582

Public

Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

Published in New England Journal of Medicine • Dec 13, 2022

Authors:

Jennifer R. Brown

Barbara Eichhorst

Peter Hillmen

Abstract

BACKGROUND: In a multinational, phase 3, head-to-head trial, ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater specificity, as treatment for relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)...

Subject

Ibrutinib

Chronic lymphocytic leukemia

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!